We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 22, 2022

De-Escalated Axillary Treatment After Neoadjuvant Systemic Therapy According to the MARI Protocol in Clinically Node-Positive Breast Cancer

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol
Breast Cancer Res Treat 2022 May 01;193(1)37-48, AA van Loevezijn, MEM van der Noordaa, MPM Stokkel, ED van Werkhoven, EJ Groen, CE Loo, PHM Elkhuizen, GS Sonke, NS Russell, FH van Duijnhoven, MTFD Vrancken Peeters

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading